Authors
Latest:
Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and CancerHuman saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
Latest:
Exploring Novel Treatment Options in Patients With RRMMThe panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Liquid Biopsy Imaging May Show Benefit in Li-Fraumeni Syndrome ScreeningFunding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Advanced Bladder Cancer: Future Directions in CareClosing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.
Latest:
Molecular Profiling in Metastatic Colorectal CancerABSTRACT: Colorectal cancer (CRC) is a commonly diagnosed malignancy. Although chemotherapy remains the backbone of treatment, the landscape of treating metastatic CRC (mCRC) is changing with the understanding of its heterogeneity and molecular blueprint. Colon cancer sidedness has proven to hold prognostic implications, with right-sided tumors having higher incidence of BRAF and KRAS mutations and being microsatellite instability–high (MSI-H); overall, they have a worse prognosis compared with left sided-tumors. Results of molecular research have demonstrated the need to profile each mCRC patient for RAS and BRAF mutations, MSI-H status, HER2 amplifications, and NTRK fusions. Ongoing clinical trials using targeted agents aim to further improve survival outcomes. We emphasize the epidemiology, knowledge of primary tumor location, and mutational landscape of mCRC, as well as novel treatment options for patients harboring unique subtypes of these characteristics.
Latest:
Updated SIO/ASCO Guidelines Recommend Integrative Therapies to Reduce Anxiety/Depression in Patients With CancerLinda E. Carlson, PhD, RPsych, discusses the recent updates from SIO/ASCO to the anxiety and depression guidelines for patients with cancer.
Latest:
Value of Geriatric Assessment in Patients With Genitourinary CarcinomaThis work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
Latest:
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Latest:
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Latest:
Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case ReportA case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Clinical Pearls on Recent Advances and the Future of Treatment in RCCMehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Latest:
Deepu Madduri, MD, on Research in Multiple Myeloma This Past YearThe expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
